IBRNvsSBIOETF Comparison
VS
iShares Neuroscience and Healthcare ETF (IBRN) belongs to the Healthcare Technology segment. ALPS Medical Breakthroughs ETF (SBIO) is part of the Tomorrow's Treatments segment. Both ETFs have the same top 2 sector exposures: Healthcare and Non-Corporate. IBRN is less expensive with a Total Expense Ratio (TER) of 0.47%, versus 0.5% for SBIO. IBRN is up 20.57% year-to-date (YTD) with +$2M in YTD flows. SBIO performs better with 30.61% YTD performance, and +$70M in YTD flows. Run a side-by-side ETF comparison of IBRN and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/01/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN SBIO | +6.36%+5.17% | +10.03%+26.33% | +20.57%+30.61% | +55.97%+86.12% | +69.91%+128.54% | n/a+45.09% |
| Flows | IBRN SBIO | +$2M+$29M | +$2M+$44M | +$2M+$70M | +$2M+$82M | +$759K+$51M | -+$12M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN SBIO | +26.38%+34.33% | +25.83%+30.80% | +25.21%+31.07% | n/a+33.89% |
| Max drawdown | IBRN SBIO | -9.28%-8.12% | -9.28%-12.63% | -34.98%-42.12% | n/a-52.50% |
| Max drawdown duration | IBRN SBIO | 40d39d | 40d60d | 338d331d | n/a1479d |
Trading data
IBRN | SBIO | |
Last sale 9/2/2026 at 1:30 PM | $39.46 | $67.89 |
| Previous close 09/01/2026 | $38.94 | $66.86 |
| Consolidated volume 09/01/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/2/2026 at 1:30 PM
Live
Closed
IBRN | SBIO | |
|---|---|---|
| Last price | $39.46 | $67.89 |
| 1D performance | +1.33% | +1.54% |
| AuM | $7.79 M | $240.41 M |
| E/R | 0.47% | 0.5% |
Characteristics
IBRN | SBIO | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | iShares | ALPS |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | S-Network Medical Breakthroughs Index |
| N° of holdings | 69 | 102 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
IBRN
USA
73.57%
Other
26.43%
SBIO
USA
88.64%
Other
11.36%
Sectors
IBRN
Healthcare
99.87%
Other
0.13%
SBIO
Healthcare
98.51%
Other
1.49%
Advertisement
Diversification
IBRN
Total weight of top 15 holdings out of 15
64.26%
SBIO
Total weight of top 15 holdings out of 15
42.78%
Top 15 holdings
Data as of July 31, 2026
IBRN
Dianthus Therapeutics, Inc.
5.45%
Xenon Pharmaceuticals, Inc.
4.83%
Praxis Precision Medicines, Inc.
4.72%
ACADIA Pharmaceuticals, Inc.
4.66%
Arrowhead Pharmaceuticals, Inc.
4.65%
Alkermes Plc
4.55%
Neurocrine Biosciences, Inc.
4.41%
Scholar Rock Holding Corp.
4.31%
PTC Therapeutics, Inc.
4.15%
Biogen, Inc.
4.15%
Axsome Therapeutics, Inc.
3.93%
argenx SE
3.82%
Denali Therapeutics, Inc.
3.76%
Dyne Therapeutics, Inc.
3.53%
Edgewise Therapeutics, Inc.
3.35%
SBIO
Crinetics Pharmaceuticals, Inc.
4.75%
Apogee Therapeutics, Inc.
4.48%
CG Oncology, Inc.
3.39%
Xenon Pharmaceuticals, Inc.
3.26%
Dianthus Therapeutics, Inc.
3.15%
Oruka Therapeutics, Inc.
3.14%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.56%
ACADIA Pharmaceuticals, Inc.
2.39%
Veradermics, Inc.
2.36%
Dyne Therapeutics, Inc.
2.25%
Edgewise Therapeutics, Inc.
2.23%
Relay Therapeutics, Inc.
2.22%
Denali Therapeutics, Inc.
1.97%
Structure Therapeutics, Inc.
1.84%
Frequently asked questions about IBRN and SBIO
How have the IBRN and SBIO ETFs performed in 2026?
As of September 1, 2026, IBRN is up 20.57% year-to-date (YTD), while SBIO has returned 30.61%. That puts SBIO better performer ahead so far this year.
Which ETF is attracting more investor money: IBRN or SBIO?
Year-to-date, the IBRN ETF saw +$2M in flows, compared to +$70M for SBIO.
Which ETF is more volatile: IBRN or SBIO?
Over the past year, IBRN had a volatility of 25.83%, while SBIO experienced 30.8%.
Which ETF is bigger: IBRN or SBIO?
As of September 1, 2026, IBRN holds $7.79 M in assets under management (AUM), while SBIO manages $240.41 M.
What sectors do the IBRN and SBIO ETFs invest in?
IBRN leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the IBRN ETF and SBIO ETF?
IBRN top holdings include Dianthus Therapeutics, Inc., Xenon Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc.. SBIO holds in its top three: Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc..
Which ETF is more diversified: IBRN or SBIO?
IBRN holds 69 securities with 64.26% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 42.78%.
Advertisement
Latest news about IBRN & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
